Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-Year Study of Taranabant in Obese Patients (Weight Loss and Prevention of Weight Regain)
2005-002454-21Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of taranabant in obesity (4 arms), sponsored by Merck & Co. Primary endpoints: Change in body weight at Week 52, Proportion of patients with ≥5% weight loss at Week 52 and 1 more. Started Jun 2005; status: terminated.
02
Drugs
taranabant
03
Conditions
obesity
Beyond the preview
Go deeper on 2005-002454-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002454-21.